title: Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells.
abstract: Blood monocytes and CD34(+) haemopoietic progenitor cells, as well as certain leukaemic cell lines, acquire characteristics of mature dendritic cells (DC) after stimulation with calcium ionophore (CI). We studied whether the in vitro treatment of primary human acute myelogenous leukaemia (AML) cells with CI leads to differentiation towards DC. Blast cells derived from nine AML patients were cultured in the presence of either CI or an established differentiation cocktail consisting of granulocyte-macrophage colony-stimulating factor plus interleukin 4 and tumour necrosis factor-alpha for 5-7 d. Microscopic examination revealed that under both conditions, AML cells were shifted along the DC pathway. In seven out of nine cases, CI-cultivation led to a higher proportion of cells with dendritic morphology. The percentage of CD40 and CD86 expressing cells was significantly increased upon CI treatment compared with cytokine-cultured cells. DC molecules as CD80 and CD83 were up-regulated upon calcium mobilization of AML cells in four out of nine samples. In four cases, CI-treated stimulator cells induced an enhanced proliferative allogeneic T-cell response compared with cytokine-treated stimulator cells. In conclusion, these data demonstrate that CI treatment is an alternative in vitro strategy to differentiate human AML cells into DC.
authors.affiliation: Institute of Immunology, University of Vienna, Austria. Martina.Waclavicek@univie.ac.at
authors.forename: M
authors.initials: M
authors.lastname: Waclavicek
authors.forename: A
authors.initials: A
authors.lastname: Berer
authors.forename: L
authors.initials: L
authors.lastname: Oehler
authors.forename: J
authors.initials: J
authors.lastname: Stöckl
authors.forename: E
authors.initials: E
authors.lastname: Schloegl
authors.forename: O
authors.initials: O
authors.lastname: Majdic
authors.forename: W
authors.initials: W
authors.lastname: Knapp
mesh_terms: D015415:Biomarkers / Q000032:analysis; D000001:Calcimycin / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D003713:Dendritic Cells / Q000473:pathology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D007167:Immunotherapy; D015847:Interleukin-4 / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D015415:Biomarkers; D007476:Ionophores; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D000001:Calcimycin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D002118:Calcium